本文選題：芪蛭通絡(luò)膠囊 + 步長(zhǎng)腦心通膠囊�。� 參考：《大連醫(yī)科大學(xué)》2016年碩士論文

【摘要】：目的:觀察芪蛭通絡(luò)膠囊治療缺血性腦卒中(氣虛血瘀證)恢復(fù)期的療效與安全性。方法:本研究采用隨機(jī)、雙盲、陽(yáng)性藥和安慰劑平行對(duì)照的實(shí)驗(yàn)方法,選取2013年11月至2015年8月與我院住院期間符合急性缺血性腦卒中發(fā)病恢復(fù)期的36名患者,隨機(jī)分為芪蛭通絡(luò)膠囊組、腦心通組和安慰劑組,其中芪蛭通絡(luò)膠囊組18例,腦心通組和安慰劑組各9例。療效觀察指標(biāo)為簡(jiǎn)化Fugl-Meyer運(yùn)動(dòng)功能(上肢、下肢)、西方失語(yǔ)癥成套測(cè)驗(yàn)(WAB)、BI評(píng)分、中醫(yī)證候評(píng)分(氣虛、血瘀)。安全性觀察指標(biāo)為:血常規(guī)、尿常規(guī)、便常規(guī)、肝腎功和不良反應(yīng)。結(jié)果:芪蛭通絡(luò)膠囊組、腦心通組和安慰劑組的一般資料組間比較差別均無(wú)統(tǒng)計(jì)學(xué)意義,兩組基線資料均衡性良好。芪蛭組與腦心通組均較安慰劑組對(duì)下肢運(yùn)動(dòng)功能障礙改善有明顯療效,芪蛭組在發(fā)病前90天對(duì)下肢功能改善較腦心通組明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組及腦心通組對(duì)上肢運(yùn)動(dòng)功能障礙改善均較安慰劑組有效,芪蛭組改善更明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組與腦心通組對(duì)運(yùn)動(dòng)功能障礙的改善均較安慰劑組有效,芪蛭組比腦心通組改善更明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組與腦心通組較安慰劑組對(duì)AQ評(píng)分改善明顯,芪蛭組在發(fā)病前90天對(duì)AQ評(píng)分改善較腦心通組明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組與腦心通組對(duì)血瘀癥狀改善均較安慰劑組明顯有效,芪蛭組較腦心通組對(duì)血瘀癥狀改善更有效,組間比較雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組比腦心通組和安慰劑組對(duì)氣虛癥狀改善明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。芪蛭組的中醫(yī)證候臨床有效率在發(fā)病第90天和第12周較腦心通組和安慰劑組改善明顯,(P=0.0041),有明顯統(tǒng)計(jì)學(xué)差異。結(jié)論:1、下肢運(yùn)動(dòng)功能障礙的改善情況:芪蛭組與腦心通組對(duì)下肢運(yùn)動(dòng)功能障礙改善均較安慰劑組明顯有效,芪蛭組在發(fā)病前90天對(duì)下肢功能改善較腦心通組明顯,雖無(wú)統(tǒng)計(jì)學(xué)差異,但趨勢(shì)明顯。2、芪蛭組在對(duì)氣虛血瘀證中醫(yī)證候量化積分改善方面較腦心通組與安慰劑組明顯有效,(P0.0041),有統(tǒng)計(jì)學(xué)意義。芪蛭組與腦心通組在對(duì)語(yǔ)言障礙的改善、日常生活能力的改善、上肢運(yùn)動(dòng)功能障礙改善、運(yùn)動(dòng)功能障礙的改善方面較安慰劑組明顯有效,而芪蛭組在對(duì)語(yǔ)言障礙的改善、上肢運(yùn)動(dòng)功能障礙改善、運(yùn)動(dòng)功能障礙的改善方面較腦心通組略有效。
[Abstract]:Objective: to observe the efficacy and safety of Qizhi Tongluo capsule in the treatment of ischemic stroke (qi deficiency and blood stasis syndrome). Methods: a randomized, double-blind, positive-drug and placebo-controlled trial was conducted in 36 patients who met the convalescent stage of acute ischemic stroke from November 2013 to August 2015. Qizhitongluo capsule group, Naoxintong group and placebo group were randomly divided into Qizhitongluo capsule group (18 cases), Naoxintong group (9 cases) and placebo group (9 cases). The therapeutic effects were as follows: simplified Fugl-Meyer motor function (upper limb, lower limb), Western aphasia test (WAB) and BI score, TCM syndrome score (Qi deficiency, blood stasis). The safety indexes were blood routine, urine routine, stool routine, liver and kidney function and adverse reaction. Results: there was no significant difference between the two groups in general data of Qizhitongluo capsule group, Naoxintong group and placebo group. The baseline data of the two groups were well balanced. Compared with placebo group, Qizhi group and Naoxintong group had obvious effect on the improvement of lower limb motor dysfunction. The improvement of lower limb function in Qizhi group was more obvious than that in Naoxintong group 90 days before the onset of disease, although there was no statistical difference, but the trend was obvious. Qizhi group and Naoxintong group were more effective than placebo group in the improvement of upper limb motor dysfunction. The improvement of Qizhi group was more obvious, although there was no statistical difference, but the trend was obvious. The improvement of motor dysfunction in Qizhi group and Naoxintong group was more effective than that in placebo group. The improvement of Qizhi group was more obvious than that of Naoxintong group, although there was no statistical difference, but the trend was obvious. The AQ score of Qizhi group and Naoxintong group was significantly improved than that of placebo group, and the AQ score of Qizhi group was significantly improved than that of Naoxintong group 90 days before onset, although there was no statistical difference, but the trend was obvious. Both Qizhi group and Naoxintong group were more effective than placebo group in improving blood stasis symptoms, Qizhi group was more effective than Naoxintong group in improving blood stasis symptom, although there was no statistical difference between the two groups, the trend was obvious. Qi deficiency symptoms were improved significantly in Qizhi group compared with Naoxintong group and placebo group, although there was no statistical difference, but the trend was obvious. The effective rate of TCM syndromes in Qizhi group was significantly improved on the 90th and 12th week compared with the Naoxintong group and the placebo group (P0. 0041). Conclusion: the improvement of lower extremity motor dysfunction in Qizhi group and Naoxintong group is more effective than that in placebo group, and the improvement of lower limb function in Qizhi group is more obvious than that in Naoxintong group 90 days before onset. Although there was no statistical difference, the trend was obvious. The Qizhi group was more effective than the Naoxintong group and the placebo group in improving the quantitative integral of TCM syndromes of qi deficiency and blood stasis syndrome (P0.0041). Qizhi group and Naoxintong group were more effective than placebo group in improving speech disorder, daily living ability, upper limb motor dysfunction and motor dysfunction. The improvement of upper limb motor dysfunction was more effective than that of Naoxintong group.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R277.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李天兵;;通絡(luò)膠囊治療急性冠狀動(dòng)脈綜合征心肌梗死療效觀察[J];中國(guó)保健營(yíng)養(yǎng);2013年02期

2 孟煉,陳生文,伍峰,盧紅,毛軍;補(bǔ)血通絡(luò)膠囊治療成人股骨頭缺血性壞死[J];四川中醫(yī);2003年01期

3 李嘉榮;張振華;;丹芪通絡(luò)膠囊的質(zhì)量研究[J];臨床合理用藥雜志;2010年14期

4 白民剛;谷剛;樸德成;張桂英;李普海;楊春;史定一;姜華靜;徐宏武;郭剛恒;;海川通絡(luò)膠囊治療一過(guò)性腦缺血64例臨床研究[J];中醫(yī)雜志;2002年12期

5 丁舒;陳慧;;通絡(luò)膠囊對(duì)冠心病患者治療前后多參數(shù)對(duì)比觀察[J];中國(guó)現(xiàn)代藥物應(yīng)用;2008年18期

6 白民剛,朱立鳴,谷剛,楊春,李普海,張桂英;海川通絡(luò)膠囊治療短暫性腦缺血64例[J];山東中醫(yī)雜志;2001年12期

7 楊紅海;徐光輝;;益腦通絡(luò)膠囊對(duì)微血管內(nèi)血栓形成預(yù)防作用的實(shí)驗(yàn)研究[J];中國(guó)民康醫(yī)學(xué);2007年18期

8 李新萍;趙新民;馮彥敏;肖維剛;張欣;段瑞生;靳彥華;;桂龍通絡(luò)膠囊對(duì)小量高血壓性腦出血預(yù)后的影響[J];中國(guó)醫(yī)藥導(dǎo)刊;2008年06期

9 李瑞林;張葆現(xiàn);趙尚清;孫會(huì)仙;;溶栓通絡(luò)膠囊治療血栓閉塞性脈管炎[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2013年10期

10 于麗鳳;王恩峰;張浩;;通絡(luò)膠囊治療胸痹的臨床研究[J];黑龍江醫(yī)藥;2003年01期

相關(guān)會(huì)議論文 前9條

1 王永霞;吳先杰;任琳琳;王彩歌;王幼平;朱明軍;;調(diào)脂通絡(luò)膠囊對(duì)家兔動(dòng)脈粥樣硬化的影響[A];第三屆“黃河心血管病防治論壇”資料匯編[C];2012年

2 羅文匯;孫冬梅;李智勇;畢曉黎;;通絡(luò)膠囊質(zhì)量標(biāo)準(zhǔn)的研究[A];中藥化學(xué)研究與藥物創(chuàng)新——中華中醫(yī)藥學(xué)會(huì)中藥化學(xué)分會(huì)2006年度學(xué)術(shù)研討會(huì)論文集[C];2006年

3 陳建強(qiáng);馬謙;;熄風(fēng)通絡(luò)膠囊治療缺血性中風(fēng)急性期200例臨床觀察[A];中華中醫(yī)藥學(xué)會(huì)腦病分會(huì)成立大會(huì)暨2008年全國(guó)中醫(yī)腦病學(xué)術(shù)研討會(huì)論文匯編[C];2008年

4 王超;呂鳴;;自制通絡(luò)膠囊治療腰腿痛60例臨床療效分析[A];第四屆全國(guó)中西醫(yī)結(jié)合風(fēng)濕類疾病學(xué)術(shù)會(huì)議論文匯編[C];2000年

5 趙希鋒;;益氣通絡(luò)膠囊在心腦疾病治療中的應(yīng)用[A];甘肅省中醫(yī)藥學(xué)會(huì)2010年會(huì)員代表大會(huì)暨學(xué)術(shù)年會(huì)論文匯編[C];2010年

6 張梅奎;尹嶺;姚斌;劉育英;趙秀梅;鄭一;宋春杰;劉鳳榮;;益腦通絡(luò)膠囊對(duì)微血管內(nèi)血栓形成預(yù)防作用的實(shí)驗(yàn)研究[A];首屆全國(guó)功能神經(jīng)影像學(xué)和神經(jīng)信息學(xué)研討會(huì)論文匯編[C];2003年

7 王永霞;王彩歌;王幼平;任琳琳;朱明軍;吳先杰;;調(diào)脂通絡(luò)膠囊對(duì)心肌IRI大鼠炎癥反應(yīng)的影響[A];第三屆“黃河心血管病防治論壇”資料匯編[C];2012年

8 傅警龍;;養(yǎng)陰通絡(luò)膠囊治療系統(tǒng)性紅斑狼瘡體會(huì)[A];科技創(chuàng)新與節(jié)能減排——吉林省第五屆科學(xué)技術(shù)學(xué)術(shù)年會(huì)論文集（下冊(cè)）[C];2008年

9 王永霞;黃國(guó)強(qiáng);宋歡歡;代建宇;原雙星;李彬;王幼平;朱明軍;;調(diào)脂通絡(luò)膠囊對(duì)大鼠心梗后心室重構(gòu)MMPs、TIMPs的影響[A];第四屆“黃河心血管病防治論壇”資料匯編[C];2013年

相關(guān)重要報(bào)紙文章 前2條

1 莊夢(mèng);夏天治風(fēng)濕，選雙蟻祛濕通絡(luò)膠囊[N];健康報(bào);2012年

2 陸菁菁;民族醫(yī)藥正在發(fā)力[N];醫(yī)藥經(jīng)濟(jì)報(bào);2011年

相關(guān)博士學(xué)位論文 前1條

1 張梅奎;益腦通絡(luò)膠囊對(duì)缺血性中風(fēng)神經(jīng)細(xì)胞保護(hù)作用的實(shí)驗(yàn)研究[D];北京中醫(yī)藥大學(xué);2003年

相關(guān)碩士學(xué)位論文 前5條

1 程源;益心通絡(luò)膠囊的活血化瘀藥效學(xué)研究及其生物檢定法初探[D];北京中醫(yī)藥大學(xué);2016年

2 孫秀婷;基于QbD的龍加通絡(luò)膠囊質(zhì)量控制研究[D];天津大學(xué);2015年

3 李霞;芪蛭通絡(luò)膠囊治療缺血性腦卒中恢復(fù)期的臨床研究[D];大連醫(yī)科大學(xué);2016年

4 談tD忠;復(fù)方通絡(luò)膠囊的藥學(xué)研究[D];南京中醫(yī)藥大學(xué);2007年

5 宋歡歡;調(diào)脂通絡(luò)膠囊對(duì)心梗大鼠心功能及心肌細(xì)胞凋亡相關(guān)基因的影響[D];河南中醫(yī)學(xué)院;2014年

，

本文編號(hào)：2063465